When does the Talvey (tarlatamab) patent expire?
I don’t have enough provided information to state Talvey’s exact patent expiration date(s). Patent expiry depends on which specific patent(s) covering Talvey you mean (drug substance, formulations, methods of use, combinations) and which country’s filings apply.
If you share the market of interest (for example, U.S., EU, UK, or a specific country) or the patent number(s) you’re looking at, I can help map the likely expiry timeline based on that information.
Does Talvey have multiple patents—so expiry isn’t one single date?
Yes. For most cancer drugs, companies typically have a “patent thicket,” meaning several patents can cover different aspects of the product and may expire at different times. That can affect when generics/biosimilars (or other competition) are allowed, depending on what’s still protected.
To answer precisely for Talvey, I’d need either:
- the patent numbers / publication numbers you’re tracking, or
- the jurisdiction and the source you’re using to look up the timeline.
What would delay market competition if a patent expires?
Even if one patent expires, others may still provide coverage. Also, regulatory exclusivities can extend effective market protection beyond the last patent expiry for some products (the exact rule depends on jurisdiction).
If you tell me which country’s “patent expiration” question you care about (U.S. vs EU rules differ), I can tailor what delays competition are most relevant.
How to find the most relevant Talvey patents for “expiration”
The most useful starting points are usually:
- the FDA Orange Book (U.S., for listed patents and exclusivities), or
- the EU/UK equivalent listings for medicinal product protection, or
- patent registers using the applicant/assignee and the drug name plus tarlatamab.
If you paste links or the patent identifiers you see there, I can interpret them and translate them into an expiry timeline.
Quick clarifying question
Which jurisdiction do you mean by “Talvey patent expiration” (U.S., EU, UK, or another country), and do you have any patent number(s) or the source listing you’re using?